-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

Benzinga·08/12/2026 16:02:51
语音播报
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.